Imaging Endpoints

We’re excited to announce that Imaging Endpoints will be attending the ASCO GI Cancers Symposium 2025 🌟 Meet our top medical, scientific, and operations experts on January 23-24, 2025, as we showcase how our advanced imaging solutions are transforming oncology clinical trials and driving breakthroughs in GI cancer research. 📍 Event Location: Moscone West, San Francisco, CA 📅 Dates: January 23-24, 2025 🤝 Schedule a meeting with our experts: https://hubs.li/Q0309YWv0 Let’s connect to explore how we can collaborate to advance science and improve patient outcomes. #ASCOGI2025 #OncologyResearch #ClinicalTrials #ImagingEndpoints

Enhancing CLL Clinical Trials: The Vital Role of BICR in Imaging Assessments 📊 Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults, mainly affecting those aged 65 and older. While CT and MRI are not crucial for initial diagnosis, they are essential in clinical research. The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) assessment criteria are key for evaluating treatment responses, combining tumor measurements, clinical data, and biomarkers for a comprehensive understanding of patient outcomes. The heterogeneity of CLL, especially the common B-cell variant, highlights the need for precise imaging assessments. At Imaging Endpoints, we integrate imaging with clinical data per iwCLL standards. Interpreting subtle imaging changes presents challenges, necessitating regular training for reviewers to ensure consistency. To improve patient outcomes in CLL trials, we establish standardized imaging protocols and clear, optimized response criteria. To see how Imaging Endpoints is committed to supporting CLL clinical trials https://hubs.li/Q02_WldY0 #ImagingEndpoints #MedicalImaging #ClinicalTrials #CLL #ChronicLymphocyticLeukemia #BICR

🌟 Wrapping up an Incredible ASH 2024! 🌟 This year at ASH 2024, we proudly showcased our innovative solutions and engaged with the brightest minds in hematology and oncology. Here's a glimpse of what made this event so special: 👉 Team Spirit: The Imaging Endpoints team was in full force, connecting with partners, sharing our expertise, and building meaningful collaborations. 👉 Expert Discussions: Our booth served as a hub for insightful conversations, where we discussed the latest trends and solutions in imaging and clinical research. 👉 Cutting-Edge Showcase: From our booth design to our demonstrations, we showed the world how Imaging Endpoints is "Connecting Imaging to the Cure." Swipe through to relive the highlights and thank you to everyone who stopped by Booth # 2155 to make this event a resounding success! We look forward to more opportunities to connect and innovate together. Let’s keep transforming the clinical trials landscape, one breakthrough at a time! 💡✨ #ASH2024 #ImagingEndpoints #InnovationInOncology

It’s been a great day meeting with our partners at #ASH24! We look forward to connecting tomorrow. Imaging Endpoints Jatinder Kaur Ronald Korn Doug Dean Burkett Samuel Lofland Julia Giles - MS, PMP Agapi Tshamjyan Samantha Corallo Samira Farough

🎯 Countdown to ASH 2024: Redefining Clinical Trials with Imaging Excellence! 🎯 From December 7th–9th, meet us at Booth #2155 during the 2024 ASH Annual Meeting and discover how we’re pushing the boundaries of clinical research with specialized imaging solutions. 💡 What Sets Us Apart? 🔹 State-of-the-art imaging technologies delivering precise and actionable trial data 🔹 Expertise in streamlining imaging endpoints for faster trial execution 🔹 Proven solutions tailored to support oncology and hematology research 🤝 Your Partner in Clinical Success: Let’s connect to explore how our imaging capabilities can empower your clinical trials. Schedule a meeting with our experts today to see how we can collaborate for impactful results. 📅 Book your appointment here: https://hubs.li/Q02-84610 Join us in advancing oncology research through imaging-driven clinical trials. Let’s shape the future of medical breakthroughs together! #ASH2024 #ImagingExcellence #OncologyResearch #ClinicalTrials #ImagingCRO #MedicalImaging #InnovativeResearch #ImagingEndpoints

🌟 Pioneering Neurology Research at Clinical Endpoints 🌟 As a leading Site Management Organization (SMO), Clinical Endpoints is dedicated to supporting clinical studies focused on neurological diseases. With extensive experience in conditions like Alzheimer’s and Parkinson’s, our clinical sites are driving progress in understanding and treating these disorders. We’re actively involved in several groundbreaking studies targeting amyloid plaques, tau tangles, and neuroinflammation - key mechanisms behind cognitive decline. Our commitment to excellence ensures that we’re Connecting Patients to Hope, offering innovative solutions to transform outcomes for patients and their families. 🔗 Learn More https://hubs.li/Q02ZxzJW0 #NeurologyResearch #ClinicalTrials #SiteManagementOrganization #ClinicalEndpoints #AlzheimersResearch #ParkinsonsResearch #HopeForPatients

The landscape of lymphoma treatment is evolving with the integration of advanced imaging biomarkers, enhancing how we assess therapy responses. Lymphomas, including non-Hodgkin and Hodgkin types, are significant blood cancers with increasing incidence globally. Traditional size-based imaging methods often fall short in evaluating treatment efficacy, prompting a shift towards more sophisticated imaging techniques. Functional imaging, particularly 18F-FDG PET/CT, is revolutionizing our approach. By measuring metabolic activity rather than just size, it provides deeper insights into tumor response assessments. With superior sensitivity and specificity compared to traditional CT, methods like the Deauville 5-point scale in Lugano criteria are improving patient management decisions. Furthermore, innovative approaches like DWI and PET/MRI are paving the way for more accurate assessments of nodal involvement and tumor microenvironments. Bone marrow biopsies continue to play a crucial role alongside advanced imaging when it comes to response assessments. Clinical trials utilizing PET/CT are critical for standardizing response criteria and enhancing treatment evaluations. IE recently published a white paper entitled "Optimizing Imaging Response Criteria for Improved Outcomes in Oncology Clinical Trials ," available online at: https://hubs.li/Q02Z0-6M0 which frames and highlights IE's unparalleled approach to image analysis customization and optimization, including clarifications and modifications to applicable criteria like Lugano. Our physicians and operations experts, including our Chief Medical Officer Dr. Korn, are available to meet at ASH 2024 to discuss how we can leverage our experience and expertise to support your upcoming trials. Reserve your time here. https://hubs.li/Q02Z0SH40 #Lymphoma #ImagingBiomarkers #PETCT #ImagingEndpoints #ClinicalTrials #MedicalImaging #Oncology #ASH2024

🌟 Join Us at the 2024 ASH Annual Meeting! 🌟 We’re thrilled to participate in this year’s ASH Annual Meeting from December 7th–9th at Booth #2155! Let’s connect and discuss how we can collaborate to revolutionize clinical trials with state-of-the-art solutions and unmatched expertise. 📌 What’s in store for you? ✅ Customized approaches to accelerate your clinical trial timelines ✅ Advanced technologies enhancing data precision and operational efficiency ✅ Expert insights to drive impactful results in oncology research 💡 Your Opportunity to Connect: Schedule a meeting with our Medical and Operational Leaders to explore how we can empower your clinical research journey. Click here to secure your spot: https://hubs.li/Q02YJnyw0 Let’s shape the future of clinical trials together! Don’t miss out—visit us at ASH 2024 and see how we’re transforming possibilities into success. #ASH2024 #ClinicalTrials #PharmaInnovation #Biotech #OncologyResearch #MedicalExperts #ClinicalResearch #ImagingEndpoints

Whitepaper: Optimizing Imaging Response Criteria for Improved Outcomes in Oncology Clinical Trials! Imaging Endpoints latest whitepaper dives deep into optimizing imaging response criteria for oncology clinical trials with strategies for RECIST, Lugano, RANO, PCWG3 and other criteria. Learn how our innovative approach can streamline trial success, accelerate timelines, and support regulatory approvals. With a 95% marketing authorization success rate, IE is at the forefront of clinical trial innovation—let us show you how we can help. 📥 Download the whitepaper for free, on-demand, here https://hubs.li/Q02XTsRS0 #OncologyTrials #ClinicalResearch #ImagingEndpoints #InnovationInOncology #TrialOptimization

🔬 Meet Us at the 2024 ASH Annual Meeting! 🔬 Excited to connect with innovators in the pharma and biotech industry at the 2024 ASH Annual Meeting! This December 7th–9th, we’ll be at Booth #2155, ready to explore how our cutting-edge solutions can take your clinical trials to the next level. At this pivotal event, schedule a dedicated meeting with our Medical and Operations Experts to dive deep into: ✅ Tailored strategies that accelerate clinical trials ✅ Innovative technologies designed to enhance data accuracy and streamline operations ✅ Collaborative insights to drive impactful outcomes in oncology research Don’t miss this opportunity to see how we’re reshaping clinical trial success with advanced methodologies and a commitment to excellence in research. Click here https://hubs.li/Q02Xhlyj0 to secure your meeting time—let’s create impactful results together! Join us in transforming the future of clinical trials. We look forward to connecting at ASH 2024! #ASH2024 #ClinicalTrials #PharmaInnovation #Biotech #OncologyResearch #MedicalExperts #ClinicalResearch #ImagingEndpoints